Cargando…
Tissue-resident memory T cells in immune-related adverse events: friend or foe?
Many cancer patients experience toxicity during checkpoint blockade immunotherapy, which often leads to treatment discontinuation. To this end, understanding the mechanisms mediating immune-related adverse events (irAE) should ultimately enable improvement in clinical outcomes. Recent work has revea...
Autores principales: | Reschke, Robin, Gajewski, Thomas F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078118/ https://www.ncbi.nlm.nih.gov/pubmed/37035636 http://dx.doi.org/10.1080/2162402X.2023.2197358 |
Ejemplares similares
-
Human Th17 cells in patients with cancer: Friends or foe?
por: Greten, Tim F., et al.
Publicado: (2012) -
Friend or foe: A novel role of β-defensins in tumor development
por: Röhrl, Johann, et al.
Publicado: (2012) -
Interleukin-21 in cancer immunotherapy: Friend or foe?
por: Stolfi, Carmine, et al.
Publicado: (2012) -
Neuroprotective actions of 2,4-dinitrophenol: Friend or
foe?
por: Ferreira, Sérgio Teixeira, et al.
Publicado: (2007) -
Friend or foe: How plants discriminate between pathogenic and mutualistic bacteria
por: Calla, Bernarda
Publicado: (2022)